10x Genomics (NASDAQ:TXG) Issues Quarterly Earnings Results

10x Genomics (NASDAQ:TXG) released its earnings results on Thursday. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.12, FiscalAI reports. 10x Genomics had a negative return on equity of 9.33% and a negative net margin of 12.18%. The business had revenue of $150.67 million for the quarter, compared to the consensus estimate of $147.96 million. During the same quarter in the previous year, the business earned ($0.22) earnings per share. 10x Genomics’s quarterly revenue was up 1.1% on a year-over-year basis.

Here are the key takeaways from 10x Genomics’ conference call:

• Third-quarter revenue was $150.7 million, up 1% year over year, and 10X raised its 2026 revenue outlook to $625 million–$635 million. Excluding patent-litigation settlement revenue, the range implies 4%–6% growth over 2025.
• Atera commercial shipments began in September, and the company now expects to ship about 50 instruments by year-end, up from its prior estimate of 40. Management cited strong demand, while noting that production, installation, and customer training—not orders—are limiting the pace of rollout.
• Spatial consumables revenue grew 16%, with strong Xenium demand; management expects double-digit spatial consumables growth in Q4 as Atera consumables shipments begin. It said customer interest in Atera’s whole-transcriptome option has exceeded expectations.
• Instrument revenue fell 43% as sales of Chromium, Visium, and Xenium instruments declined, partly reflecting customers waiting for Atera. Gross margin was 75% in Q3, but management expects it to fall to the low-to-mid 60% range in Q4 and to be lower in 2027 as Atera placements make the mix more instrument-heavy.
• Single-cell reaction volumes grew at a double-digit rate, supported by Flex Apex adoption, but single-cell consumables revenue rose only 1%. Management said the lower price per reaction for Apex is weighing on revenue as customers shift toward the platform.

10x Genomics Stock Up 0.9%

Shares of NASDAQ TXG traded up $0.54 during midday trading on Friday, hitting $58.59. 1,113,168 shares of the company’s stock were exchanged, compared to its average volume of 3,017,974. The firm has a market capitalization of $7.63 billion, a PE ratio of -99.40 and a beta of 2.03. 10x Genomics has a 12 month low of $13.58 and a 12 month high of $102.81. The company’s 50 day moving average price is $74.06 and its 200 day moving average price is $41.41.

Insiders Place Their Bets

In other 10x Genomics news, CEO Serge Saxonov sold 25,000 shares of the firm’s stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $81.22, for a total transaction of $2,030,500.00. Following the completion of the sale, the chief executive officer owned 1,050,249 shares of the company’s stock, valued at $85,301,223.78. This trade represents a 2.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Adam Taich sold 46,388 shares of the firm’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $64.57, for a total value of $2,995,273.16. Following the sale, the chief financial officer directly owned 316,344 shares of the company’s stock, valued at $20,426,332.08. This represents a 12.79% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 179,333 shares of company stock worth $11,810,070 in the last quarter. Company insiders own 8.84% of the company’s stock.

Key 10x Genomics News

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: Q3 revenue was $150.7 million, above the $148.0 million consensus, while the loss of $0.15 per share was narrower than estimates of $0.27–$0.29 and the year-ago loss of $0.22. 10x Genomics Reports Third Quarter 2026 Financial Results
• Neutral Sentiment: The company forecast full-year 2026 revenue of $625 million to $635 million and aims to ship about 50 Atera systems by year-end. Citi raised its price target to $60 but maintained a Neutral rating; another report put the average target at $68. 2026 revenue outlook and Atera shipments Citi raises price target, keeps neutral rating
• Negative Sentiment: Despite the earnings beat, TXG declined following the results. Revenue grew only 1.1% year over year, and the company remained unprofitable, with a negative net margin, which may have weighed on investor reaction. Q3 sales top estimates but stock drops

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Royal Bank Of Canada assumed coverage on 10x Genomics in a research note on Tuesday, September 1st. They issued a “sector perform” rating and a $70.00 price target for the company. Stephens lowered shares of 10x Genomics from an “overweight” rating to an “equal weight” rating in a research report on Friday, October 23rd. Piper Sandler increased their price target on shares of 10x Genomics from $47.00 to $80.00 and gave the company a “neutral” rating in a research note on Monday, September 28th. Leerink Partners lifted their price objective on shares of 10x Genomics from $40.00 to $90.00 and gave the company a “market perform” rating in a research report on Tuesday, September 29th. Finally, Argus assumed coverage on shares of 10x Genomics in a research note on Monday, September 28th. They set a “buy” rating and a $110.00 price objective on the stock. Five analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $67.40.

10x Genomics Company Profile

10x Genomics, Inc is a life sciences technology company that develops tools for analyzing biological systems at the single-cell and spatial levels. Its technologies are designed to help researchers study gene expression, cellular interactions, tissue organization and other biological processes in greater detail than conventional laboratory methods.

The company’s product portfolio includes the Chromium platform for single-cell analysis, the Visium platform for spatial transcriptomics, and the Xenium platform for high-resolution in situ analysis of tissue samples.